Maxim downgraded Citius Pharmaceuticals (CTXR) to Hold from Buy.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTXR:
- Citius Pharmaceuticals Reports Q1 2025 Earnings and Strategic Developments
- Citius Pharmaceuticals reports Q2 EPS (11c) vs. (7c) last year
- Citius Pharmaceuticals Poised for Growth with Key Milestones and Promising Product Pipeline
- Citius Pharmaceuticals target adjusted to $4 for split at H.C. Wainwright
- Biotech Alert: Searches spiking for these stocks today